Explore the growth potential of the Alzheimer's disease-modifying therapies (DMTs) market as lecanemab gains FDA approval in 2023. With several late-stage trials underway, anticipate market shifts ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Lilly's valuation seems reasonable given its growth prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Biosimilars, once met with skepticism, are now an undeniable force in the global pharmaceutical market. As several ...